Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicaid Coverage For Smoking Cessation Gains Steam

This article was originally published in The Tan Sheet

Executive Summary

An amendment proposed for the Senate's health care reform legislation follows the House in covering comprehensive smoking-cessation services, including OTC products, across the Medicaid community

You may also be interested in...



Researchers’ Doubts About Nicotine Replacement Therapy Threaten Coverage

Nicotine replacement therapy sales could take a hit if health policy makers heed advice not to increase coverage for the products at the expense of other allegedly more effective interventions. A recent study found NRT is no more effective in helping people quit smoking than going cold turkey.

Researchers’ Doubts About Nicotine Replacement Therapy Threaten Coverage

Nicotine replacement therapy sales could take a hit if health policy makers heed advice not to increase coverage for the products at the expense of other allegedly more effective interventions. A recent study found NRT is no more effective in helping people quit smoking than going cold turkey.

Fate Of OTCs In Health Savings Accounts Rests In Capitol Hill Negotiations

Congress' work to reconcile its two health care reform bills includes deciding whether OTC drugs - when prescribed by doctors - are eligible for reimbursement from health savings or flexible spending accounts

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103638

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel